Innoviva (INVA) Total Debt Growth (3y) (2013 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 6.94% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 50.25% |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.07% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | -16.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.59% |
| Dec 31, 2025 | -21.87% |
| Sep 30, 2025 | -21.88% |
| Jun 30, 2025 | 67.18% |
| Mar 31, 2025 | 67.21% |
| Dec 31, 2024 | 4.34% |
| Sep 30, 2024 | 4.51% |
| Jun 30, 2024 | 4.68% |
| Mar 31, 2024 | 4.84% |
| Dec 31, 2023 | 5.00% |
| Sep 30, 2023 | 5.15% |
| Jun 30, 2023 | 5.31% |
| Mar 31, 2023 | 5.46% |
| Dec 31, 2022 | 12.74% |
| Sep 30, 2022 | 11.57% |
| Jun 30, 2022 | -37.13% |
| Mar 31, 2022 | -37.04% |
| Dec 31, 2021 | 1.02% |
| Sep 30, 2021 | 0.98% |
| Jun 30, 2021 | -7.11% |
| Mar 31, 2021 | -7.16% |
| Dec 31, 2020 | -13.68% |
| Sep 30, 2020 | -14.04% |
| Jun 30, 2020 | -2.87% |
| Mar 31, 2020 | -7.00% |
| Dec 31, 2019 | -19.24% |
| Sep 30, 2019 | -6.89% |
| Jun 30, 2019 | -7.22% |
| Mar 31, 2019 | -7.33% |
| Dec 31, 2018 | -7.40% |
| Sep 30, 2018 | -7.98% |
| Jun 30, 2018 | 0.22% |
| Mar 31, 2018 | 0.53% |
| Dec 31, 2017 | 8.32% |
| Sep 30, 2017 | 9.47% |
| Jun 30, 2017 | -2.58% |
| Dec 31, 2016 | 161.60% |
| Mar 31, 2015 | 3,222.85% |
| Dec 31, 2014 | 1,797.74% |
| Sep 30, 2014 | 1,516.01% |
| Jun 30, 2014 | 1,305.72% |
| Dec 31, 2013 | 425.91% |